Tumor-Associated Glycoprotein 72 (TAG-72), also known as the cancer-associated glycoprotein, is a high–molecular weight mucin-like glycoprotein complex described in the literature as being expressed in a range of epithelial malignancies, particularly adenocarcinomas, while showing low and restricted expression in most normal adult tissues. Peer-reviewed studies in tumor biology and immunohistochemistry describe TAG-72 as a tumor-associated antigen linked to aberrant glycosylation patterns observed in malignant epithelial transformation, although expression levels and detection may vary depending on tumor type and analytical methods used.

Biological Significance & Research Value

TAG-72 is a tumor-associated mucin-like glycoprotein antigen expressed in a subset of adenocarcinoma cells. It is associated with altered glycosylation patterns characteristic of malignant epithelial differentiation. Expression has been reported in colorectal, ovarian, pancreatic, breast, and subsets of pulmonary adenocarcinomas in immunohistochemical studies, although expression is heterogeneous and not uniformly present across all cases. Its generally restricted expression in normal tissues supports its use as a tumor-associated biomarker in immunohistochemistry (IHC), while acknowledging variability depending on tissue context and assay conditions.

Applications & Use in Diagnostics

TAG-72 IHC antibodies have been used as part of broader diagnostic immunohistochemistry panels in tumor evaluation, including cases of suspected adenocarcinoma. In diagnostic pathology studies, TAG-72 positivity may support epithelial adenocarcinoma differentiation when interpreted in combination with established markers such as CEA, MOC-31, and Ber-EP4, within a comprehensive antibody panel. Its role is generally adjunctive and supportive rather than primary, and it should be interpreted alongside more lineage-specific markers when distinguishing adenocarcinoma from non-epithelial tumors, including malignant mesothelioma. TAG-72 expression may also assist in supporting identification of metastatic adenocarcinoma in tissue biopsies, depending on the overall immunoprofile.

Key Features of CE/IVD Anti-TAG-72 Antibodies for IHC

• Validated for use in formalin-fixed, paraffin-embedded (FFPE) tissue sections in immunohistochemistry workflows.
• CE/IVD classification indicating intended use in in vitro diagnostic applications within regulated laboratory environments.
• High specificity monoclonal antibody clones targeting TAG-72-associated epitope complexes, with performance dependent on validated assay conditions.
• Optimized for chromogenic detection systems (e.g., DAB) in routine pathology staining workflows.
• Suitable for inclusion in broader tumor diagnostic panels supporting adenocarcinoma biomarker assessment.